Nynomic AG's Path to Recovery and Growth in 2026

Nynomic AG's latest research update from NuWays AG classifies the company as a "BUY," with a target price of EUR 21 over the next 12 months. The company's preliminary FY25 figures show revenues of €92.6 million, a 10% decrease year-on-year due to weak demand, particularly in the Clean Tech segment. EBIT stood at €2.0 million, reflecting a 2% margin, impacted by reduced sales and €1.5 million in one-off expenses from the NyFit2025 cost-cutting initiative.

However, during Q4, Nynomic saw a significant upswing, with revenues reaching €27.7 million and an EBIT margin of approximately 12.6%, boosted by regular seasonality and NyFit2025's cost savings. Management projects FY26 sales of €100-105 million, driven by demand in Pharma, MedTech, and Semiconductor sectors, targeting an EBIT margin of 6-8%.

Beyond near-term growth, Nynomic benefits from LayTec's precision measurement tools in semiconductor manufacturing, pivotal for AI datacentres. With a robust balance sheet featuring €14.5 million in cash by FY25's end, and a ~50% recent valuation increase, the recommendation remains a "BUY" at a €21 price target.